DK0653427T3 - Galanthaminderivater, en fremgangsmåde til deres fremstilling og deres anvendelse som lægemidler - Google Patents

Galanthaminderivater, en fremgangsmåde til deres fremstilling og deres anvendelse som lægemidler

Info

Publication number
DK0653427T3
DK0653427T3 DK94115959T DK94115959T DK0653427T3 DK 0653427 T3 DK0653427 T3 DK 0653427T3 DK 94115959 T DK94115959 T DK 94115959T DK 94115959 T DK94115959 T DK 94115959T DK 0653427 T3 DK0653427 T3 DK 0653427T3
Authority
DK
Denmark
Prior art keywords
hydrogen
pharmaceuticals
preparation
alkylaminocarbonyl
alkyl
Prior art date
Application number
DK94115959T
Other languages
English (en)
Inventor
W Jr Kosley Raymond
Larry Davis
Veronica Taberna
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Application granted granted Critical
Publication of DK0653427T3 publication Critical patent/DK0653427T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10Spiro-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/06Peri-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK94115959T 1993-10-15 1994-10-10 Galanthaminderivater, en fremgangsmåde til deres fremstilling og deres anvendelse som lægemidler DK0653427T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/137,440 US6323195B1 (en) 1993-10-15 1993-10-15 Galanthamine derivatives as acetylcholinesterase inhibitors

Publications (1)

Publication Number Publication Date
DK0653427T3 true DK0653427T3 (da) 2002-04-15

Family

ID=22477446

Family Applications (1)

Application Number Title Priority Date Filing Date
DK94115959T DK0653427T3 (da) 1993-10-15 1994-10-10 Galanthaminderivater, en fremgangsmåde til deres fremstilling og deres anvendelse som lægemidler

Country Status (23)

Country Link
US (2) US6323195B1 (da)
EP (2) EP1020470A3 (da)
JP (1) JP2664344B2 (da)
KR (1) KR0169114B1 (da)
CN (1) CN1039911C (da)
AT (1) ATE212348T1 (da)
AU (1) AU696249B2 (da)
CA (1) CA2118174C (da)
CZ (1) CZ287071B6 (da)
DE (1) DE69429708T2 (da)
DK (1) DK0653427T3 (da)
EG (1) EG20472A (da)
ES (1) ES2171428T3 (da)
FI (1) FI108723B (da)
IL (1) IL111274A (da)
NO (1) NO310415B1 (da)
NZ (1) NZ264683A (da)
PL (1) PL177730B1 (da)
PT (1) PT653427E (da)
RO (1) RO114133B1 (da)
RU (1) RU2114850C1 (da)
TW (1) TW363969B (da)
ZA (1) ZA948062B (da)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9514821D0 (en) * 1995-07-19 1995-09-20 Sod Conseils Rech Applic Galanthamine derivatives
AT403803B (de) 1996-04-19 1998-05-25 Sanochemia Ltd Neue benzazepinderivate, diese enthaltende arzneimittel und verwendung derselben zum herstellen von arzneimitteln
EP1133230A4 (en) * 1998-11-23 2004-05-26 Bonnie M Davis DOSAGE FORMULAS FOR ACETYLCHOLINESTERASE INHIBITORS
DE69912311T2 (de) 1998-12-24 2004-07-29 Janssen Pharmaceutica N.V. Galantamin-zusammensetzung mit gesteuerter freisetzung
US8603546B2 (en) * 1999-01-11 2013-12-10 Herbaceuticals Inc. Herbal supplement for increased muscle strength and endurance for athletes
ATE355066T1 (de) * 1999-01-11 2006-03-15 Atanas Russinov Djananov Nahrungszusatz aus kräutern zur steigerung der muskulären kraft und ausdauer von athleten
ES2211056T3 (es) * 1999-03-31 2004-07-01 Eisai Co., Ltd. Composiciones estabilizadas que contienen farmacos nootropicos.
DK1237539T3 (da) * 1999-10-26 2006-02-27 Janssen Pharmaceutica Nv Oral oplösning indeholdende galanthamin og et södemiddel
WO2001043697A2 (en) * 1999-12-10 2001-06-21 Bonnie Davis Analogs of galanthamine and lycoramine as modulators of nicotinic receptors
PL202463B1 (pl) 2000-03-31 2009-06-30 Sanochemia Pharmazeutika Ag Pochodne galantaminy, sposób ich wytwarzania, środek leczniczy zawierajacy te pochodne, zastosowanie pochodnej galantaminy do wytwarzania środków leczniczych, sposób wytwarzania środków leczniczych oraz sposób oddzielania (+)- i (-)-izomerów
US20030162770A1 (en) * 2002-02-22 2003-08-28 Davis Bonnie M. Use of modulators of nicotinic receptors for treatment of cognitive dysfunction
US20050143350A1 (en) * 2003-11-19 2005-06-30 Seed John C. Combination drug therapy to treat obesity
US20050191349A1 (en) * 2003-12-31 2005-09-01 Garth Boehm Galantamine formulations
CA2552114A1 (en) * 2003-12-31 2005-07-21 Actavis Group Hf Solid dosage formulations of galantamine
US20080045500A1 (en) * 2004-07-01 2008-02-21 Eisai R&D Management Co., Ltd. Nerve Regeneration Stimulator
EP1895995A2 (en) * 2005-05-13 2008-03-12 Alza Corporation Multilayer drug system for the delivery of galantamine
US20080188510A1 (en) * 2005-05-23 2008-08-07 Eisai R & D Management Co., Ltd. Novel methods using zonisamide
EP1777222A1 (en) 2005-09-22 2007-04-25 Galantos Pharma GmbH Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment
US20090253654A1 (en) 2005-09-22 2009-10-08 Galantos Pharma Gmbh Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment
JP2009508903A (ja) * 2005-09-22 2009-03-05 ガラントス ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング 認知障害を伴う疾患の治療に用いるための脳血液関門透過性が改善されたコリン作用増強剤
US20070104771A1 (en) * 2005-09-23 2007-05-10 Jay Audett Transdermal galantamine delivery system
DK2137192T3 (da) 2008-04-14 2014-05-26 Neurodyn Life Sciences Inc Derivater af galantamin som prodrugs til behandling af humane hjernesygdomme
AU2010275431A1 (en) * 2009-07-23 2012-02-23 Shire Llc Galantamine amino acid and peptide prodrugs and uses thereof
WO2013160728A1 (en) 2012-04-26 2013-10-31 Alma Mater Studiorum - Universita' Di Bologna Dual targeting compounds for the treatment of alzheimer's disease
EP3628315A1 (en) 2018-09-28 2020-04-01 Université de Caen Normandie Combination of acetylcholinesterase inhibitor and 5-ht4 receptor agonist as neuroprotective agent in the treatment of neurodegenerative diseases
CN113292420A (zh) * 2021-05-27 2021-08-24 神隆医药(常熟)有限公司 加兰他敏中间体原料2-溴-5-羟基-4-甲氧基苯甲酸回收方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL122665B1 (en) 1978-11-21 1982-08-31 Edinen Zentar Chim Process for preparing novel dienones of narvedine type and their derivatives
US4663318A (en) 1986-01-15 1987-05-05 Bonnie Davis Method of treating Alzheimer's disease
US6150354A (en) * 1987-01-15 2000-11-21 Bonnie Davis Compounds for the treatment of Alzheimer's disease
ATE411026T1 (de) * 1987-05-04 2008-10-15 Bonnie Davis Mittel zur behandlung der alzheimer-krankheit
NL8800350A (nl) 1988-02-12 1989-09-01 Stichting Biomedical Research Synthetische galanthamine-derivaten, werkwijze voor het bereiden daarvan, en farmaceutische samenstellingen.
ATE183084T1 (de) 1991-05-14 1999-08-15 Ernir Snorrason Behandlung des ermüdungssyndroms mit cholinesteraseinhibitoren
US5231093A (en) * 1991-10-01 1993-07-27 Hoechst-Roussel Pharmaceuticals Incorporated Carbamate derivatives of 4-amino-3-isoxazolidinones, 3-amino-1-hydroxypyrrolidin-2-ones and 1-amino-1-cyclopropanecarboxylic acid analogs
US5153193A (en) 1991-10-01 1992-10-06 Hoechst-Roussel Pharmaceuticals Incorporated Carbamate derivatives of 4-amino-3-isoxazolidinones, 3-amino-1-hydroxypyrrolidin-2-ones and 1-amino-1-cyclopropanecarboxylic acid analogs

Also Published As

Publication number Publication date
NZ264683A (en) 1998-03-25
EP0653427B1 (en) 2002-01-23
EG20472A (en) 1999-05-31
US5777108A (en) 1998-07-07
EP0653427A1 (en) 1995-05-17
RO114133B1 (ro) 1999-01-29
JPH07188240A (ja) 1995-07-25
PT653427E (pt) 2002-06-28
ATE212348T1 (de) 2002-02-15
CZ254694A3 (en) 1995-09-13
IL111274A0 (en) 1994-12-29
RU2114850C1 (ru) 1998-07-10
FI108723B (fi) 2002-03-15
FI944821A0 (fi) 1994-10-13
CA2118174C (en) 2000-01-18
FI944821A (fi) 1995-04-16
EP1020470A3 (en) 2000-07-26
IL111274A (en) 2000-11-21
NO943893D0 (no) 1994-10-14
NO943893L (no) 1995-04-18
CN1111245A (zh) 1995-11-08
RU94036448A (ru) 1996-09-10
JP2664344B2 (ja) 1997-10-15
ZA948062B (en) 1995-06-06
US6323195B1 (en) 2001-11-27
KR0169114B1 (ko) 1999-01-15
DE69429708T2 (de) 2002-08-29
CZ287071B6 (en) 2000-08-16
DE69429708D1 (de) 2002-03-14
ES2171428T3 (es) 2002-09-16
PL305456A1 (en) 1995-04-18
AU7581494A (en) 1995-05-04
CN1039911C (zh) 1998-09-23
TW363969B (en) 1999-07-11
AU696249B2 (en) 1998-09-03
CA2118174A1 (en) 1995-04-16
NO310415B1 (no) 2001-07-02
PL177730B1 (pl) 2000-01-31
KR950011443A (ko) 1995-05-15
EP1020470A2 (en) 2000-07-19

Similar Documents

Publication Publication Date Title
DK0653427T3 (da) Galanthaminderivater, en fremgangsmåde til deres fremstilling og deres anvendelse som lægemidler
DK0552329T3 (da) Methylen-oxindol-derivater og fremgangsmåde til deres fremstilling
ZA932168B (en) Naphthylalkylamines, process for preparing them and pharmaceutical compositions containing them
DK0648771T3 (da) Galanthamin-derivat, en fremgangsmåde til dets fremstilling og dets anvendelse som medikament
DK0587499T3 (da) Benzopyranforbindelser, fremgangsmåde til deres fremstilling og deres anvendelse som cellebeskyttelsesmidler
DK0649846T3 (da) Galanthaminderivater, en fremgangsmåde til deres fremstilling og deres anvendelse som lægemidler
HU903197D0 (en) Process for producing 5,11-dihydrodibenzo(b,e) (1,4)-thiazepine derivatives and medicament preparatives containing these compounds
DK0605474T3 (da) Carbamatanaloger af thiaphysovenin, farmaceutiske præparater og fremgangsmåder til inhibering af cholinesteraser
AU5473596A (en) New indole, indazole benzisoxazole compounds, their process of preparation and the pharmaceutical compositions which contain them
NO953557L (no) Antitumorpreparater og fremgangsmåte for deres fremstilling
GR3034253T3 (en) Fluoro-substituted benzoylpropionic acid derivatives
NO303494B1 (no) Tetrahydronaftalenderivater, fremgangsmÕte for deres fremstilling og farmas°ytisk preparat inneholdende et slikt derivat, samt mellomprodukter